— Magid Abou-Gharbia, Ph.D, FRSC is currently Laura H. Carnell Professor of Medicinal Chemistry and Founding Director of the Moulder Center for Drug Discovery Research(MCDDR) at the School of Pharmacy, Temple University, Philadelphia, PA. As the Founding Director, he was responsible for Setting and implementing Moulder Center research strategies to bridging preclinical research with clinical research “from Bench to Patient-Bedside” and promoting the school’s research and entrepreneurial enterprise. Prior to joining Temple University in 2008, Magid spent 26 years at Wyeth Pharmaceuticals where he was Senior Vice President Discovery Research. In my role I directed research of 500 scientists at 4 US sites (PA,NJ, NY and MA) and 150 Chemists in Hyderabad, India. Abou-Gharbia’s research team efforts resulted in the Discovery of 10-marketed drugs across multiple therapeutic areas including two drugs for treatment of depression Effexor and Pristiq and four Drugs for treatment of Cancer and increasing the life expectancy of patients in need (Antibody Drug Conjugate Mylotarg, m-TOR inhibitor Torisel, Two Kinase inhibitors Bosulif and Neratinib).His research contributions in the past 15 years at Temple University resulted in establishing Moulder Center for Drug Discovery Research (https://www.youtube.com/watch?v=2yotuH6ZU0c),a State-of-the-Art academic Drug discovery Center. Moulder Center’s accomplishments included receiving several research grants and contract research (>$30M), the publications of numerous research papers in peer-reviewed journals, the filing of over 35 US patents and the formation of 4spin off companies based on licensing of his Center’s IP to external companies. Magid received numerous awards for his scientific achievements and serves on the Scientific Advisory Board of several companies and Scientific and professional societies and has adjunct professor appointments at several universities in the US and abroad. His career research achievements resulted in more than 128 US patents, over 350 worldwide Patents, 325 publications, invited lectures and presentations. Current Research Activity: Medicinal Chemistry and Drug Design, particularly in the areas of glutamate Transporters Enhancers for treatment of cocaine addiction, Alcohol use and cerebral palsy, epigenetic modulators anti-cancer agents, anti-infectives and drugs for treating neuronal disorders.